Beta Drugs (NSE:BETA) Institutional Ownership: 0.07% (As of Jul. 29, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

NSE:BETA Beta Drugs Ltd NSE:BETA
94 GF Score
Price ₹2,233.20
GF Value ₹1,993.18
Valuation Modestly Overvalued
! 7 Warning Signs
View Full Analysis

What is Beta Drugs Institutional Ownership?

Beta Drugs NSE:BETA +5.85% 94 Institutional Ownership is 0.07% as of Jul. 29, 2026. GuruFocus rates NSE:BETA with a GF Score™ of 94/100 and a GF Value™ of ₹1,993.18 (Modestly Overvalued). The stock has 7 warning signs investors should review.

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Beta Drugs's institutional ownership is 0.07%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Beta Drugs's Insider Ownership is 0.00%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Beta Drugs's Float Percentage Of Total Shares Outstanding is 0.00%.

Beta Drugs Institutional Ownership Historical Data

* Premium members only.

The historical data trend for Beta Drugs's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Beta Drugs Institutional Ownership Chart

Beta Drugs Historical Data

The historical data trend for Beta Drugs can be seen below:

2025-06-30 2025-07-31 2025-08-31 2025-09-30 2025-10-31 2025-11-30 2025-12-31 2026-01-31 2026-02-28 2026-03-31
Institutional Ownership 0.07 0.07 0.07 0.07 0.07 0.07 0.07 0.07 0.07 0.07
NSE:BETA
94GF Score
Beta Drugs Ltd NSE:BETA
Institutional Ownership is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Beta Drugs Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.

What does a Institutional Ownership of 0.07% mean?
Beta Drugs (NSE:BETA) has a Institutional Ownership of 0.07% as of Jul. 29, 2026. Institutional ownership equals the percent of shares owned by financial institutions relative to total shares. View historical data on Beta Drugs and its competitors.
Is Beta Drugs' Institutional Ownership too high?
Beta Drugs' current Institutional Ownership is 0.07%. Overall, Beta Drugs has a GF Score™ of 94/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Beta Drugs' Institutional Ownership compare to ZTS?
Beta Drugs' Institutional Ownership of 0.07% can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Institutional Ownership for a Drug Manufacturers company?
A good Institutional Ownership depends on the Drug Manufacturers industry context. However, Institutional Ownership should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Institutional Ownership mean?
A high Institutional Ownership can signal that a stock is expensive relative to its fundamentals. Institutional ownership equals the percent of shares owned by financial institutions relative to total shares. View historical data on Beta Drugs and its competitors. Beta Drugs's current Institutional Ownership is 0.07%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Beta Drugs stock overvalued right now?
Based on GuruFocus' analysis, Beta Drugs (NSE:BETA) is currently considered Modestly Overvalued. The stock's GF Value™ is ₹1,993.18, compared to a current price of ₹2,233.20 — trading 12% above its estimated fair value. The current Institutional Ownership is 0.07%. Beta Drugs' overall GF Score™ is 94/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Institutional Ownership calculated?
Institutional Ownership is calculated from a company's financial statements. For Beta Drugs (NSE:BETA), the current Institutional Ownership is 0.07% as of Jul. 29, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Beta Drugs (NSE:BETA) Overvalued in 2026?

Based on GuruFocus' analysis, Beta Drugs stock appears to be overvalued. The current stock price of ₹2,233.20 is trading 12% above its estimated GF Value™ of ₹1,993.18. GuruFocus considers Beta Drugs to be Modestly Overvalued.

Key valuation signals for NSE:BETA:

  • Institutional Ownership: 0.07%
  • GF Value™: ₹1,993.18 vs. price of ₹2,233.20 (12% above fair value)
  • GF Score™: 94/100 with 7 warning signs

No single metric tells the full story. See the NSE:BETA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Beta Drugs Business Description

Address SCO-184, First Floor, Sector-5, Panchkula, HR, IND, 134114
Beta Drugs Ltd operates in the pharmaceutical industry. The company manufactures and sells Oncology products in the form of tablets, capsules, oral formulations, and injections. It sells the products in India and also exports them to other countries, of which key revenue is derived from the sales made in India.
94GF Score

Get the complete analysis for NSE:BETA

Institutional Ownership is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹2,233.20
Price
₹1,993.18
GF Value